Table 2.
The association of NRF2, GSTM3, SOD2 and GPX3 polymorphisms with the risk for testicular GCT development.
| Genotype | Testicular GCT Patients, n (%) |
Control Group, n (%) |
OR (95%CI) 1 | p | OR (95%CI) 2 | p |
|---|---|---|---|---|---|---|
| NRF2 (rs6721961) | ||||||
| AA | 2 (2) | 3 (4) | 1.00 3 | 1.00 3 | ||
| CC + CA | 84 (98) | 73 (96) | 1.72 (0.28–10.61) |
0.556 | 1.42 (0.20–9.72) |
0.719 |
| GSTM3 (rs1332018) | ||||||
| CC | 10 (12) | 19 (22) | 1.00 3 | 1.00 3 | ||
| AA + AC | 73 (88) | 67 (78) | 2.07 (0.90–4.76) |
0.087 | 1.23 (0.48–3.10) |
0.662 |
| SOD2 (rs4880) | ||||||
| CC + CT | 54 (67) | 69 (79) | 1.00 3 | 1.00 3 | ||
| TT | 26 (33) | 18 (21) | 1.84 (0.91–3.71) |
0.086 | 2.12 (0.97–4.62) |
0.057 |
| GPX3 (rs8177412) | ||||||
| TT | 38 (44) | 58 (67) | 1.00 3 | 1.00 3 | ||
| TC + CC | 48 (56) | 28 (33) | 2.61 (1.40–4.86) |
0.002 | 2.14 (1.09–4.19) |
0.027 |
1 OR—crude odds ratio; 2 OR adjusted to other genotypes; CI—confidence interval; 3 reference group.